Comparison of efficacy and safety of topical betamethasone valerate 0.1% with narrowband-UVB in atopic dermatitis
DOI:
https://doi.org/10.66344/jpad.28.2.2018.1236Keywords:
Atopic dermatitis, betamethasone Valerate 0.1%, efficacy, NB-UVB, safetyAbstract
Objective To compare the efficacy and safety of topical betamethasone valerate 0.1% with narrowband ultraviolet B (NB-UVB) therapy in atopic dermatitis. Method Sixty patients with AD fulfilling the inclusion criteria were entered in the study. Patients were divided into 2 groups. Group A were given betamethasone valerate 0.1% twice a day for 4 weeks. Group B were given NB-UVB thrice a week for 8 weeks. Starting dose was 75% of minimal erythema dose (MED) for the skin type III and IV. Dose was increased by 20% on each visit as tolerated by the patients. During treatment patients were assessed at 2nd and 4th week for betamethasone valerate and 2nd, 4th, 6th and 8th week for NB-UVB. Results 84% patients in group A (betamethasone) showed >50% reduction in Scoring of Atopic Dermatitis (SCORAD) whereas 94% patients in group B (NB-UVB) showed >50% reduction in SCORAD (p=0.554). Side effects were seen in 34% patients in group A and 20% in group B. Conclusion Both betamethasone valerate 0.1% and NB-UVB are almost equal in terms of efficacy but NB-UVB is more safe than betamethasone valerate 0.1%.ÂReferences
Friedmann PS, Holden CA. Atopic dermatitis. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. Rook’s Textbook of Dermatology, 8th edn. London: Blackwell Science; 2010. P. 24.1-18.
Leung DY, Bieber T. Atopic dermatitis. Lancet. 2003;361:151-60.
Novak N, Bieber T, Leung DYM. Immune mechanisms leading to atopic dermatitis. J Allergy Clin Immunol. 2003;112:128-39.
Baldo A, Cafiero M, Di Caterino P, Di Costanzo L. Tacrolimus ointment in the management of atopic dermatitis. Clin Cosmet Invest Dermatol. 2009;2:1-7.
Schmitt J, Schakel K , Schmitt N. Systemic treatment of severe atopic dermatitis: A systematic review. Acta Derm Venereol. 2007;87:100-11.
Reynolds NJ, Franklin V, Gray JC , Diffey BL, Farr PM. Narrowband ultraviolet B and broadband ultraviolet A phototherapy in atopic dermatitis. Lancet. 2001;357:2012-6.
Jekler J, Larko O. UVB phototherapy of atopic dermatitis. Br J Dermatol. 1988;119:697-705.
Dogra S, Kanwar AJ. Narrowband UVB phototherapy in dermatology. Indian J Dermatol Venereol Leprol. 2004;70:205-9.
Ahmed I, Ansari M, Malick K. Childhood eczema: a comparative analysis. J Pak Assoc Dermatol. 2003;13:164-70.
Nasreen S, Wahid Z, Ahmed A. Atopic dermatitis: Frequency of associated disorder in children. J Pak Assoc Dermatol. 2005;15:125-9.
Kanwar AJ, De D. Epidemiology and clinical features of atopic dermatitis in India. Indian J Dermatol. 2011;56:471-5.
Johanna M, Anita R, Hannele V, Sakari R. One-year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: A randomized, double-blind, comparative trial. Acta Derm Venereol. 2010;90:170-4.
Aschoff R, Schmitt J, Knuschke P, Koch E, Bräutigam M, Meurer M. Evaluation of the atrophogenic potential of hydrocortisone 1% cream and pimecrolimus 1% cream in involved forehead skin of patients with atopic dermatitis using optical coherence tomography. Exp Dermatol. 2011;20:832-36.
Selvaag E, Caspersen L, Bech-Thomsen N, Wulf HC. Optimized UVB treatment of atopic dermatitis using skin reflectance measurements. A controlled, left-right comparison trial. Acta Derm Venereol. 2005;85:144-6.
Nakagawa H. Comparison of the efficacy and safety of 0.1% tacrolimus ointment with topical corticosteroids in adult patients with atopic dermatitis: review of randomized, double- blind clinical studies conducted in Japan. Clin Drug Investig. 2006;26:235-46.
Der-Petrossian M, Seeber A, Honigsmann H, Tanew A. Half-side comparison study on the efficacy of 8-methoxypsoralen bath- PUVA versus narrow-band ultraviolet phototherapy in patients with severe atopic dermatitis. Br J Dermatol. 2000;142:39-43.
Grundmann-Kollmann M, Behrens S, Podda M, Peter RU, Kaufmann R, Kerscher M. Phototherapy for atopic eczema with narrow-band UVB. J Am Acad Dermatol. 1999;40:995-7.
Downloads
Published
How to Cite
Issue
Section
License
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
